Karen Smith - Sucampo Pharmaceuticals Director

Director

Dr. Karen L. Smith, M.D. Ph.D. M.B.A. LLM., was appointed as Director of the Comapny, with effective from July 15, 2017. Dr. Smith brings to Sucampo over 25 years of senior leadership and executive experience with both major pharmaceutical companies and startup biotechnology organizations. Her product development expertise spans various therapeutic areas and includes over 20 major drug and device approvals in North and Latin America, Asia, Europe and Australia. From 2011 to 2015, she was a Senior Vice President of Global Medical Affairs and Global Therapeutic Area Head for Allergan, a multispecialty health care company. From 2007 to 2010, Dr. Smith served initially as AstraZeneca Vice President of External Medical Relations, and later Vice President of Global Development. She held an array of management and medical roles at the BristolMyers Squibb Company in Australia, Canada and the United States. In 2001, she was also the Chief Executive Officer of Boron Molecular, a specialist fine chemicals manufacturing company. Dr. Smith previously served on the Women Advisory Board for Ironman Corporationrationration, Susan G. Komen and Girl Scouts and is currently Advisor to the CEO of Forward Pharma since 2017.
Age 48
Tenure 7 years
Professional MarksMBA
Phone301 961-3400
Webwww.sucampo.com
Smith holds a B.A.Sc. and a B.Sc. from the Curtin University, an M.D. from the University of Warwick, a Ph.D. in oncology molecular genetics from the University of Western Australia, an M.B.A. from the University of New England and a L.L.M. in medical law from the University of Salford .

Sucampo Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Craig RamseyNational CineMedia
63
Paula MadisonNational CineMedia
63
Kurt HallNational CineMedia
58
Joseph OLearyEdgewell Personal Care
62
Mark SegallNational CineMedia
55
Scott SchneiderNational CineMedia
58
Stephen LanningNational CineMedia
62
Daniel HeinrichEdgewell Personal Care
64
Phillip MasonLincoln Electric Holdings
67
Renana TeperbergNational CineMedia
40
Amanda ButlerLincoln Electric Holdings
N/A
Lee MitchellNational CineMedia
81
Rakesh SachdevEdgewell Personal Care
64
Kathryn LincolnLincoln Electric Holdings
63
Andrew GlazeNational CineMedia
39
David GunningLincoln Electric Holdings
75
Patrick GorisLincoln Electric Holdings
46
George CorbinEdgewell Personal Care
56
William MacDonaldLincoln Electric Holdings
71
Gary WaringEdgewell Personal Care
61
James JohnsonEdgewell Personal Care
68
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals operates under Drug Manufacturers - Other classification in USA and traded on NASDAQ General Markets. It employs 1 people. Sucampo Pharmaceuticals (SCMP) is traded on NASDAQ Exchange in USA and employs 139 people.

Management Performance

Sucampo Pharmaceuticals Leadership Team

Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Munder, Independent Director
Peter Pfreundschuh, CFO, Principal Financial Officer
Matthew Donley, Executive VP of HR
Max Donley, Executive Vice President of Human Resources
Peter Kiener, Chief Scientific Officer
Matthias Alder, Executive Vice President - Business Development & Licensing
Daniel Getman, Independent Chairman of the Board
Peter Greenleaf, Chairman and CEO
Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications
Peter Lichtlen, Chief Medical Officer
Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC
Andrew Smith, Principal Accounting Officer
Timothy Walbert, Director
John Johnson, Director
Paul Edick, Director
Alex Driggs, Acting General Counsel, Corporate Secretary
Karen Smith, Director
Robert Spiegel, Director
Maureen OConnell, Independent Director
Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary

Sucampo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sucampo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sucampo Pharmaceuticals' short interest history, or implied volatility extrapolated from Sucampo Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Consideration for investing in Sucampo Stock

If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Money Managers
Screen money managers from public funds and ETFs managed around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data